Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level.

BACKGROUND: During stress, vasopressin is a potent synergistic factor of CRH as a hypothalamic stimulator of the HPA axis. The measurements of CRH and vasopressin levels are cumbersome because of their instability and short half-life. Copeptin is a more stable peptide stoichiometrically released from the same precursor molecule. The aim of our study was to compare copeptin and cortisol levels in different stress situations. METHODS: Three groups of patients with increasing stress levels were investigated: a) healthy controls without apparent stress (n=20), b) hospitalized medical patients with moderate stress (n=25) and c) surgical patients 30 minutes after extubation, with maximal stress (n=29). In all patients we assessed cortisol and copeptin levels. Copeptin levels were measured with a new sandwich immunoassay. RESULTS: Cortisol levels in controls were (median, IQ range, 486 [397-588] nmol/L), not significantly different as compared to medical patients (438 [371-612] nmol/L, p=0.69). Cortisol levels in surgical patients after extubation were higher (744 [645-1062] nmol/L p<0.01 vs controls and medical patients). Copeptin levels in controls were 4.3 [3.2-5.5] pmol/L, which was lower as compared to medical patients (17.5 [6.4-24.1], p<0.001) and surgical patients after extubation (67.5 [37.8-110.0] pmol/L, p<0.001). The correlation between copeptin levels and cortisol was r=0.46, p<0.001. CONCLUSION: Copeptin is a novel marker of the individual stress level. It more subtly mirrors moderate stress as compared to cortisol values.

Botiga virtual de vins de la comarca del Priorat

El projecte mostra el procés de desenvolupament d'una aplicació per a Internet, concretament una botiga virtual de vins, seguint el Procés Unificat de Desenvolupament de Software.

Behaviour evaluation for risk-taking adolescents (BERTA): an easy to use and assess instrument to detect adolescent risky behaviours in a clinical setting.

To create an instrument to be used in an outpatient clinic to detect adolescents prone to risk-taking behaviours. Based on previous research, five identified variables (relationship with parents and teachers, liking going to school, average grades, and level of religiosity) were used to create a screening tool to detect at least one of ten risky behaviours (tobacco, alcohol, cannabis and other illegal drugs use; sexual intercourse and sexual risky behaviour; driving while intoxicated, riding with an intoxicated driver, not always using a seat belt, and not always using a helmet). The instrument was tested using the Barcelona Adolescent Health Survey 1993. A Receiver Operating Characteristics curve was used to find the best cut-off point between high and low risk score. Odds ratios and 95% confidence intervals were calculated to detect at least one risky behaviour and for each individual behaviour. In order to assess its predictive value, the analysis was repeated using the Barcelona Adolescent Health Survey 1999. In both cases, analyses were conducted for the whole sample and for younger and older adolescents. Adolescents with a high-risk score were more likely to take at least one risky behaviour both when the whole sample was analysed and by age groups. With very few exceptions, the Behaviour Evaluation for Risk-Taking Adolescents showed significant odds ratios for each individual variable. CONCLUSION: The Behaviour Evaluation for Risk-Taking Adolescents has shown its potential as an easy to use instrument to screen for risk-taking behaviours. Future research must aim towards assessing this instrument's predictive value in the clinical setting and it's application to other populations.

Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence.

Inflammatory processes described in Parkinson’s disease (PD) and its animal models appear to be important in the progression of the pathogenesis, or even a triggering factor. Here we review that peripheral inflammation enhances the degeneration of the nigrostriatal dopaminergic system induced by different insults; different peripheral inflammations have been used, such as IL-1β and the ulcerative colitis model, as well as insults to the dopaminergic system such as 6-hydroxydopamine or lipopolysaccharide. In all cases, an increased loss of dopaminergic neurons was described; inflammation in the substantia nigra increased, displaying a great activation of microglia along with an increase in the production of cytokines such as IL-1β and TNF-α. Increased permeability or disruption of the BBB, with overexpression of the ICAM-1 adhesion molecule and infiltration of circulating monocytes into the substantia nigra, is also involved, since the depletion of circulating monocytes prevents the effects of peripheral inflammation. Data are reviewed in relation to epidemiological studies of PD.

Institutions physiques, par la marquise DU CHATELET.

Ms. autographe.

Le thème de la liberté chez Agyeya : l'apport de la fiction hindi à l'histoire intellectuelle de l'Inde moderne

Ce travail de doctorat a pour objet central l'usage du thème de la liberté dans les fictions narratives de l'auteur hindi S.H. Vatsyayan 'Agyeya' (1911-­-1987), plus précisément dans ses romans et nouvelles appartenant aux années 1936-­-1961, encadrant donc le double évènement capital pour l'histoire de l'Inde de son indépendance et de sa partition en août 1947. En basant sa recherche sur la littérature fictionnelle écrite en hindi, son objectif est de contribuer de manière féconde et novatrice à la connaissance de l'Inde moderne dans ses développements littéraires et intellectuels. La thèse de ce travail postule qu'une étude de textes fictionnels centrée sur l'analyse sémantique de la notion de « liberté » fournit, grâce à la polysémie de cette dernière et à ses multiples lexicalisations hindi (azadi, chu?kara, mukti, svadhinata, svaraj, svatantrata, etc.), une clé d'interprétation privilégiée de l'oeuvre d'Agyeya en particulier et de l'Inde moderne en général. La recherche effectuée à cette fin a été guidée par l'hypothèse suivante, à savoir que les sources fictionnelles hindi représentent, par rapport aux sources argumentatives et normatives habituellement utilisées en sciences humaines et sociales, un apport précieux de données culturelles concrètes à l'étude de l'Asie du Sud. La principale conclusion de ce travail est que la polysémie de la notion de « liberté » permet comme nulle autre de mettre en évidence le caractère foncièrement interdépendant des diverses composantes du social, dans ses dimensions politique et économique, religieuse et spirituelle, juridique et sociale, ou encore culturelle et artistique. Un deuxième résultat marquant de cette étude est la mise en lumière de l'importance grandissante qu'occupe l'individu dans la société indienne moderne. L'ouvrage débute par un chapitre introductif sur la méthode d'analyse adoptée et les critères ayant présidé à la sélection de la période, du genre textuel et de l'auteur. Le deuxième chapitre est précisément consacré à l'auteur ainsi qu'à son contexte historique et linguistique. Prolongeant cette partie de contextualisation, le troisième chapitre se concentre sur la notion de « liberté » dans l'Inde moderne en se penchant notamment sur les usages de cette notion chez quelques-­- unes de ses figures intellectuelles majeures (Aurobindo, Gandhi, Ambedkar, M.N. Roy, etc.). L'analyse chronologique et l'interprétation du thème de la liberté dans les oeuvres d'Agyeya forment la partie centrale du travail (chapitre 4). Le chapitre cinq élargit l'analyse aux essais d'Agyeya et propose un retour comparatif sur les oeuvres de l'écrivain avec ce qu'il est dit de la liberté au XXe s. chez les intellectuels indiens. La conclusion inclut une réflexion sur l'apport potentiel de cette notion aux études en sciences humaines et sociales. L'ouvrage se termine par les annexes contenant mes traductions de quelques textes emblématiques du développement de l'oeuvre d'Agyeya et par les références bibliographiques.

Nasal trauma due to continuous positive airway pressure in neonates.

PATIENTS: All neonates admitted between January 2002 and December 2007 treated by nCPAP were eligible. METHODS: Patients' noses were monitored during nCPAP. Nasal trauma was reported into three stages: (I) persistent erythema; (II) superficial ulceration; and (III) necrosis. RESULTS: 989 neonates were enrolled. Mean gestational age was 34 weeks (SD 4), mean birth weight 2142 g (SD 840). Nasal trauma was reported in 420 (42.5%) patients and it was of stage I, II and III in 371 (88.3%), 46 (11%) and 3 (0.7%) patients, respectively. Incidence and severity of trauma were inversely correlated with gestational age and birth weight. The risk of nasal trauma was greater in neonates <32 weeks of gestational age (OR 2.48, 95% CI 1.59 to 3.86), weighing <1500 g at birth (OR 2.28, 95% CI 1.43 to 3.64), treated >5 days by nCPAP (OR 5.36, 95% CI 3.82 to 7.52), or staying >14 days in the NICU (OR 1.67, 95% CI 1.22 to 2.28). Most cases of nasal trauma (90%) appeared during the first 6 days of nCPAP. Persistent visible scars were present in two cases. CONCLUSIONS: Nasal trauma is a frequent complication of nCPAP, especially in preterm neonates, but long-term cosmetic sequelae are very rare. This study provides a description of nasal trauma and proposes a simple staging system. This could serve as a basis to develop strategies of prevention and treatment of this iatrogenic event.

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

BACKGROUND The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by preventing or delaying the onset of resistance observed with BRAF inhibitors alone. This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib. METHODS We randomly assigned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation-positive melanoma to receive vemurafenib and cobimetinib (combination group) or vemurafenib and placebo (control group). The primary end point was investigator-assessed progression-free survival. RESULTS The median progression-free survival was 9.9 months in the combination group and 6.2 months in the control group (hazard ratio for death or disease progression, 0.51; 95% confidence interval [CI], 0.39 to 0.68; P<0.001). The rate of complete or partial response in the combination group was 68%, as compared with 45% in the control group (P<0.001), including rates of complete response of 10% in the combination group and 4% in the control group. Progression-free survival as assessed by independent review was similar to investigator-assessed progression-free survival. Interim analyses of overall survival showed 9-month survival rates of 81% (95% CI, 75 to 87) in the combination group and 73% (95% CI, 65 to 80) in the control group. Vemurafenib and cobimetinib was associated with a nonsignificantly higher incidence of adverse events of grade 3 or higher, as compared with vemurafenib and placebo (65% vs. 59%), and there was no significant difference in the rate of study-drug discontinuation. The number of secondary cutaneous cancers decreased with the combination therapy. CONCLUSIONS The addition of cobimetinib to vemurafenib was associated with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity. (Funded by F. Hoffmann-La Roche/Genentech; coBRIM ClinicalTrials.gov number, NCT01689519.).

Mélanges de poésie.

Poème de Tobie (1). — Mag. Alexandri Laus sapientiae divinae {40). — Pièces de vers composées par Jo. Prevost (89), Fr, Caulier (90), Lud. Hurillon (91, 93), J. Mentel (94), N. Leon. Bursarius (95), J. Fr. Mondolot. (96), Fr. Boutard (99), Am. du Mas (106), Car. Thiery (112), Ben. Thibaud (113), Fr. de Clermont Thoury (139), Pet, Neveletus. Doschius (169), Car. Fr. Thiery (184), Seb. Tripier (276), Franc. Linant (323), Jos. Rosset (351), Rob. Wallery (363), Ren. Pr. Tassin (371), Jo. Henr. Wentsel (373). — Extr. du ms. 553 du Vatican (104). — Lettre des religieux de Tiron à Jean Casimir, roi de Pologne (178). — Épitaphes et inscriptions modernes, plusieurs composées par Mabillon. — Deux vieilles épitaphes de l'église de: Lagny (262). Inscription antique de Vicence (311). — Distiques de l'abbé Serlon (355). Épitaphe. de Ratherius (356). — Qq. pièces en français et en italien.

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

BACKGROUND The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by preventing or delaying the onset of resistance observed with BRAF inhibitors alone. This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib. METHODS We randomly assigned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation-positive melanoma to receive vemurafenib and cobimetinib (combination group) or vemurafenib and placebo (control group). The primary end point was investigator-assessed progression-free survival. RESULTS The median progression-free survival was 9.9 months in the combination group and 6.2 months in the control group (hazard ratio for death or disease progression, 0.51; 95% confidence interval [CI], 0.39 to 0.68; P<0.001). The rate of complete or partial response in the combination group was 68%, as compared with 45% in the control group (P<0.001), including rates of complete response of 10% in the combination group and 4% in the control group. Progression-free survival as assessed by independent review was similar to investigator-assessed progression-free survival. Interim analyses of overall survival showed 9-month survival rates of 81% (95% CI, 75 to 87) in the combination group and 73% (95% CI, 65 to 80) in the control group. Vemurafenib and cobimetinib was associated with a nonsignificantly higher incidence of adverse events of grade 3 or higher, as compared with vemurafenib and placebo (65% vs. 59%), and there was no significant difference in the rate of study-drug discontinuation. The number of secondary cutaneous cancers decreased with the combination therapy. CONCLUSIONS The addition of cobimetinib to vemurafenib was associated with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity. (Funded by F. Hoffmann-La Roche/Genentech; coBRIM ClinicalTrials.gov number, NCT01689519.).